Bio Historical Balance Sheet

BGT Stock

0.04 0 4.65%

Trend analysis of Bio Gene Technology balance sheet accounts such as Other Current Liab of 384 K, Total Current Liabilities of 466.3 K or Total Stockholder Equity of 4.5 M provides information on Bio Gene's total assets, liabilities, and equity, which is the actual value of Bio Gene Technology to its prevalent stockholders. By breaking down trends over time using Bio Gene balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Bio Gene Technology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Gene Technology is a good buy for the upcoming year.

Bio Gene Inventory

84,753.22

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Gene Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Bio Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bio Gene Technology at a specified time, usually calculated after every quarter, six months, or one year. Bio Gene Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bio Gene and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bio currently owns. An asset can also be divided into two categories, current and non-current.

Bio Gene Balance Sheet Chart

At this time, Bio Gene's Cash And Short Term Investments are comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 5 M in 2025, despite the fact that Retained Earnings are likely to grow to (16.8 M).

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Bio Gene assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bio Gene Technology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Bio Gene balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bio Gene Technology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Bio Gene's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bio Gene Technology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Gene Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	455.2K	298.7K	343.5K	384.0K
Total Assets	3.8M	3.2M	3.6M	5.0M

Other Current Liab Total Assets

Bio Gene balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Net Receivables	Other Liab	Accounts Payable	Non Current Liabilities Total	Inventory	Short Long Term Debt Total
Total Assets		0.83	0.75	1.0	0.7	0.81	-0.98	-0.41	1.0	0.64	-0.29	1.0	0.44	0.45	0.68	0.75	1.0	0.62	0.63	0.81	0.6	-0.71	0.93	-0.71	0.68	0.16
Other Current Liab	0.83		0.97	0.79	0.81	0.55	-0.78	-0.7	0.8	0.33	-0.04	0.8	0.65	0.65	0.87	0.89	0.83	0.31	0.81	0.53	0.75	-0.86	0.81	-0.86	0.85	0.15
Total Current Liabilities	0.75	0.97		0.7	0.85	0.55	-0.69	-0.71	0.71	0.28	-0.03	0.71	0.61	0.59	0.9	0.92	0.75	0.26	0.79	0.53	0.78	-0.83	0.74	-0.83	0.91	0.17
Total Stockholder Equity	1.0	0.79	0.7		0.67	0.8	-0.98	-0.37	1.0	0.63	-0.29	1.0	0.41	0.41	0.64	0.71	1.0	0.61	0.61	0.8	0.56	-0.68	0.93	-0.69	0.64	0.16
Net Tangible Assets	0.7	0.81	0.85	0.67		0.61	-0.63	-0.83	0.65	0.23	0.17	0.65	0.8	0.56	0.9	0.75	0.71	0.19	0.94	0.53	0.91	-0.91	0.62	-0.91	0.92	0.38
Property Plant And Equipment Net	0.81	0.55	0.55	0.8	0.61		-0.76	-0.29	0.78	0.85	-0.36	0.78	0.4	0.5	0.6	0.67	0.8	0.83	0.47	0.99	0.65	-0.53	0.68	-0.53	0.61	0.26
Net Debt	-0.98	-0.78	-0.69	-0.98	-0.63	-0.76		0.28	-0.98	-0.65	0.42	-0.98	-0.34	-0.36	-0.6	-0.69	-0.98	-0.63	-0.55	-0.76	-0.5	0.6	-0.97	0.6	-0.58	0.01
Retained Earnings	-0.41	-0.7	-0.71	-0.37	-0.83	-0.29	0.28		-0.35	0.07	-0.54	-0.35	-0.89	-0.65	-0.84	-0.6	-0.42	0.1	-0.92	-0.2	-0.86	0.92	-0.27	0.92	-0.85	-0.49
Cash	1.0	0.8	0.71	1.0	0.65	0.78	-0.98	-0.35		0.63	-0.31	1.0	0.38	0.4	0.62	0.71	1.0	0.61	0.58	0.79	0.53	-0.67	0.94	-0.67	0.62	0.13
Non Current Assets Total	0.64	0.33	0.28	0.63	0.23	0.85	-0.65	0.07	0.63		-0.69	0.63	0.13	0.42	0.26	0.46	0.62	1.0	0.13	0.88	0.31	-0.18	0.6	-0.18	0.23	-0.12
Non Currrent Assets Other	-0.29	-0.04	-0.03	-0.29	0.17	-0.36	0.42	-0.54	-0.31	-0.69		-0.31	0.4	0.11	0.13	-0.18	-0.27	-0.7	0.32	-0.45	0.19	-0.33	-0.47	-0.34	0.16	0.6
Cash And Short Term Investments	1.0	0.8	0.71	1.0	0.65	0.78	-0.98	-0.35	1.0	0.63	-0.31		0.38	0.4	0.62	0.71	1.0	0.61	0.58	0.79	0.53	-0.67	0.94	-0.67	0.62	0.13
Common Stock Shares Outstanding	0.44	0.65	0.61	0.41	0.8	0.4	-0.34	-0.89	0.38	0.13	0.4	0.38		0.83	0.81	0.58	0.45	0.11	0.92	0.29	0.86	-0.86	0.32	-0.86	0.72	0.49
Other Current Assets	0.45	0.65	0.59	0.41	0.56	0.5	-0.36	-0.65	0.4	0.42	0.11	0.4	0.83		0.71	0.67	0.45	0.41	0.69	0.42	0.74	-0.66	0.35	-0.67	0.6	0.25
Other Stockholder Equity	0.68	0.87	0.9	0.64	0.9	0.6	-0.6	-0.84	0.62	0.26	0.13	0.62	0.81	0.71		0.88	0.68	0.22	0.9	0.54	0.93	-0.89	0.59	-0.89	0.94	0.39
Total Liab	0.75	0.89	0.92	0.71	0.75	0.67	-0.69	-0.6	0.71	0.46	-0.18	0.71	0.58	0.67	0.88		0.75	0.44	0.68	0.66	0.75	-0.73	0.72	-0.72	0.83	0.13
Total Current Assets	1.0	0.83	0.75	1.0	0.71	0.8	-0.98	-0.42	1.0	0.62	-0.27	1.0	0.45	0.45	0.68	0.75		0.59	0.64	0.79	0.6	-0.72	0.94	-0.72	0.68	0.16
Intangible Assets	0.62	0.31	0.26	0.61	0.19	0.83	-0.63	0.1	0.61	1.0	-0.7	0.61	0.11	0.41	0.22	0.44	0.59		0.1	0.86	0.28	-0.15	0.58	-0.15	0.2	-0.14
Common Stock	0.63	0.81	0.79	0.61	0.94	0.47	-0.55	-0.92	0.58	0.13	0.32	0.58	0.92	0.69	0.9	0.68	0.64	0.1		0.38	0.91	-0.96	0.54	-0.96	0.88	0.44
Property Plant Equipment	0.81	0.53	0.53	0.8	0.53	0.99	-0.76	-0.2	0.79	0.88	-0.45	0.79	0.29	0.42	0.54	0.66	0.79	0.86	0.38		0.57	-0.45	0.69	-0.46	0.56	0.19
Net Receivables	0.6	0.75	0.78	0.56	0.91	0.65	-0.5	-0.86	0.53	0.31	0.19	0.53	0.86	0.74	0.93	0.75	0.6	0.28	0.91	0.57		-0.87	0.45	-0.88	0.94	0.45
Other Liab	-0.71	-0.86	-0.83	-0.68	-0.91	-0.53	0.6	0.92	-0.67	-0.18	-0.33	-0.67	-0.86	-0.66	-0.89	-0.73	-0.72	-0.15	-0.96	-0.45	-0.87		-0.59	1.0	-0.89	-0.45
Accounts Payable	0.93	0.81	0.74	0.93	0.62	0.68	-0.97	-0.27	0.94	0.6	-0.47	0.94	0.32	0.35	0.59	0.72	0.94	0.58	0.54	0.69	0.45	-0.59		-0.58	0.56	-0.1
Non Current Liabilities Total	-0.71	-0.86	-0.83	-0.69	-0.91	-0.53	0.6	0.92	-0.67	-0.18	-0.34	-0.67	-0.86	-0.67	-0.89	-0.72	-0.72	-0.15	-0.96	-0.46	-0.88	1.0	-0.58		-0.89	-0.46
Inventory	0.68	0.85	0.91	0.64	0.92	0.61	-0.58	-0.85	0.62	0.23	0.16	0.62	0.72	0.6	0.94	0.83	0.68	0.2	0.88	0.56	0.94	-0.89	0.56	-0.89		0.38
Short Long Term Debt Total	0.16	0.15	0.17	0.16	0.38	0.26	0.01	-0.49	0.13	-0.12	0.6	0.13	0.49	0.25	0.39	0.13	0.16	-0.14	0.44	0.19	0.45	-0.45	-0.1	-0.46	0.38

Click cells to compare fundamentals

Bio Gene Account Relationship Matchups

Bio Gene balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.0M	7.3M	3.8M	3.2M	3.6M	5.0M
Other Current Liab	504.6K	790.2K	455.2K	298.7K	343.5K	384.0K
Total Current Liabilities	592.7K	1.0M	573.9K	345.9K	397.8K	466.3K
Total Stockholder Equity	4.2M	6.3M	3.2M	2.8M	3.2M	4.5M
Net Tangible Assets	4.6M	5.7M	3.9M	6.0M	6.9M	3.6M
Property Plant And Equipment Net	22.7K	23.0K	14.6K	19.0K	21.9K	26.0K
Net Debt	(3.9M)	(6.3M)	(3.0M)	(2.2M)	(2.0M)	(2.1M)
Retained Earnings	(11.7M)	(14.5M)	(17.4M)	(19.6M)	(17.7M)	(16.8M)
Cash	3.9M	6.3M	3.0M	2.2M	2.5M	4.1M
Non Current Assets Total	336.7K	300.1K	254.8K	222.2K	200.0K	271.5K
Non Currrent Assets Other	(336.7K)	(300.1K)	(254.8K)	203.2K	233.7K	245.3K
Cash And Short Term Investments	3.9M	6.3M	3.0M	2.2M	2.5M	4.1M
Common Stock Shares Outstanding	137.2M	153.3M	167.8M	185.8M	213.7M	141.8M
Liabilities And Stockholders Equity	5.0M	7.3M	3.8M	3.2M	3.6M	5.0M
Other Current Assets	207.1K	223.0K	144.4K	203.9K	234.5K	167.8K
Other Stockholder Equity	950.0K	863.3K	1.2M	818.5K	941.2K	715.1K
Total Liab	754.6K	1.0M	613.9K	368.4K	423.7K	601.7K
Total Current Assets	4.7M	7.0M	3.6M	2.9M	3.4M	4.6M
Accumulated Other Comprehensive Income	863.3K	1.2M	1.1M	907.0K	1.0M	743.2K
Intangible Assets	314.0K	277.1K	240.1K	203.2K	182.9K	252.5K
Common Stock	14.5M	15.1M	19.5M	21.5M	24.8M	13.0M
Property Plant Equipment	37.0K	22.7K	23.0K	14.6K	16.8K	26.6K
Net Receivables	523.8K	438.2K	445.6K	524.0K	602.6K	401.8K
Accounts Payable	88.1K	219.0K	118.7K	47.2K	42.5K	40.4K
Non Current Liabilities Total	161.9K	25.5K	40.0K	22.5K	20.3K	19.3K
Inventory	102.6K	132.9K	148.8K	70.2K	80.7K	84.8K
Short Term Investments	4.3M	5.3M	74.2K	1.5M	1.4M	2.6M
Net Invested Capital	4.2M	6.3M	3.2M	2.8M	2.5M	4.4M
Property Plant And Equipment Gross	37.0K	52.2K	50.5K	56.2K	64.7K	47.9K
Net Working Capital	4.1M	6.0M	3.0M	2.6M	2.3M	4.1M
Capital Stock	14.5M	15.1M	19.5M	21.5M	24.8M	18.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Bio Stock Analysis

When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC